Blog

FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease – Rare Disease Report


Rare Disease Report

FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
Rare Disease Report
This morning, Bioverativ Inc, announced that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell ...
FDA Accepts IND for Gene-Edited Cell Therapy BIVV003 for Treatment of Sickle Cell DiseaseMD Magazine


all 2 news articles »

Flattr this!

2018-05-16 NEWS
About Michael Zand